Frequency Therapeutics (NASDAQ:FREQ – Get Rating) released its quarterly earnings results on Wednesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03), MarketWatch Earnings reports.
FREQ stock opened at $1.27 on Friday. Frequency Therapeutics has a 52-week low of $1.17 and a 52-week high of $10.90. The company’s 50 day simple moving average is $1.91 and its 200-day simple moving average is $4.17. The company has a debt-to-equity ratio of 0.11, a quick ratio of 11.79 and a current ratio of 11.79.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in Frequency Therapeutics by 10.9% in the 2nd quarter. Bank of America Corp DE now owns 32,529 shares of the company’s stock valued at $324,000 after buying an additional 3,201 shares during the period. Citigroup Inc. increased its stake in Frequency Therapeutics by 56.6% in the 4th quarter. Citigroup Inc. now owns 9,203 shares of the company’s stock valued at $47,000 after buying an additional 3,325 shares during the period. Goldman Sachs Group Inc. increased its stake in Frequency Therapeutics by 2.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 139,420 shares of the company’s stock valued at $715,000 after buying an additional 3,728 shares during the period. Bank of New York Mellon Corp increased its stake in Frequency Therapeutics by 7.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 117,864 shares of the company’s stock valued at $832,000 after buying an additional 8,408 shares during the period. Finally, Invesco Ltd. acquired a new position in Frequency Therapeutics in the 2nd quarter valued at approximately $121,000. Hedge funds and other institutional investors own 50.64% of the company’s stock.
About Frequency Therapeutics (Get Rating)
Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.
- Get a free copy of the StockNews.com research report on Frequency Therapeutics (FREQ)
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.